Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4974248 | 0.92 | NPC1 (0.48) | RORCSTK39THRATHRB | |
| SCHEMBL4974285 | 0.88 | THRA (0.50) | RORCTHRATHRB | |
| SCHEMBL4975285 | 0.86 | S1PR2 (0.49) | STK39THRATHRB | |
| SCHEMBL4973491 | 0.84 | THRA (0.62) | THRATHRB | |
| SCHEMBL6660226 | 0.83 | THRA (0.66) | RORCTHRATHRB | |
| SCHEMBL8798887 | 0.82 | THRA (0.57) | STK39THRATHRB | |
| SCHEMBL4974056 | 0.81 | THRA (0.59) | THRATHRB | |
| SCHEMBL6662079 | 0.79 | THRA (0.47) | THRATHRB | |
| SCHEMBL8800507 | 0.79 | THRA (0.51) | THRATHRB | |
| SCHEMBL6662880 | 0.79 | THRA (0.48) | STK39THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2003-06-19 | — | — | US | claimed |
| US-6545018-B2 | Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis | PFIZER INC. | 2003-04-08 | — | — | US | claimed |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2002-04-25 | — | — | US | claimed |
| EP-1419173-B1 | PEPTIDES THAT BIND TO ATHEROSCLEROTIC LESIONS | NOVARTIS AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| US-20070264194-A1 | Peptides That Bind To Atherosclerotic Lesions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1157001-B1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1419173-A2 | PEPTIDES THAT BIND TO ATHEROSCLEROTIC LESIONS | Novartis AG (CH) | 2004-05-19 | — | — | EP | disclosed |
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2003-06-19 | — | — | US | disclosed |
| US-6545018-B2 | Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2003014145-A2 | PEPTIDES THAT BIND TO ATHEROSCLEROTIC LESIONS | NOVARTIS AG (CH) | 2003-02-20 | — | — | WO | disclosed |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | CHIANG YUAN-CHING PHOEBE (US) | 2002-04-25 | — | — | US | disclosed |
| WO-2002032408-A2 | COMBINATIONS OF A THYROMIMETIC COMPOUND AND A STATIN | NOVARTIS AG (CH) | 2002-04-25 | — | — | WO | disclosed |
| US-6326398-B1 | Oxamic acids and derivatives as thyroid receptor ligands | PFIZER INC. | 2001-12-04 | — | — | US | disclosed |
| EP-1157001-A1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000051971-A1 | OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114521-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, TSHR | RORC 183/4885STK39 3903/4885THRA 2/4885 |
| US-20070264194-A1 | Peptides That Bind To Atherosclerotic Lesions | FABP3, CCL2, VCAM1 | RORC 3332/4885STK39 3026/4885THRA 2609/4885 |
| US-20020049226-A1 | Oxamic acids and derivatives as thyroid receptor ligands | OXER1, THRA, OXGR1 | RORC 251/4885STK39 4148/4885THRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.